selumetinib – Medxy AI

The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.

Time-Restricted Eating in Overweight Adults: Effects on Sleep, Mood, and Quality of Life Remain Neutral
Mediterranean Diet Outperforms Other Dietary Patterns in Reducing Mortality via Inflammatory Pathways: Insights from a Causal Inference Analysis
Reducing Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery: The Role of Postoperative Fluid Restriction
Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial
Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COVID-19 depression diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top